natgillin/translations-raw huggingface dataset:
Imatinib Actavis 400 mg hard capsules imatinib
Imatinib Actavis 400 mg tvrde kapsule imatinib
Imatinib Actavis 50 mg hard capsules imatinib
Imatinib Actavis 50 mg tvrde kapsule imatinib
Imatinib Actavis contains lecithin (soya)
Imatinib Activis sadrži sojin lecitin
Imatinib Actavis is a medicine containing an active substance called imatinib.
Imatinib Actavis je lijek koji sadrži djelatnu tvar zvanu imatinib.
Imatinib Actavis is a ‘generic medicine’.
Lijek Imatinib Actavis je „generički lijek”.
Imatinib Actavis is also a treatment for adults for:
Imatinib Actavis se kod odraslih osoba također koristi za liječenje:
Imatinib Actavis is also a treatment for children and adolescents with CML.
Imatinib Actavis se kod djece i adolescenata također koristi za liječenje KML-a.
Imatinib Actavis is an anticancer medicine that contains the active substance imatinib.
Lijek Imatinib Actavis je antikancerogeni lijek koji sadrži djelatnu tvar imatinib.
Imatinib Actavis is available as capsules (50, 100 and 400 mg) and tablets (100 and 400 mg).
Lijek Imatinib Actavis dostupan je u kapsulama (50, 100 i 400 mg) i tabletama (100 i 400 mg).
Imatinib Actavis is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Imatinib Actavis uzima se peroralno uz obrok i veliku čašu vode kako bi se smanjio rizik od iritacije želuca i crijeva.
Imatinib Actavis is indicated for the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Imatinib Actavis je indiciran za liječenje odraslih bolesnika s inoperabilnim dermatofibrosarkomom protuberans (DFSP) i odraslih bolesnika s rekurentnim i/ili metastazirajućim DFSP-om koji nisu podobni za kirurški zahvat.
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Imatinib Actavis indiciran je za liječenje pedijatrijskih bolesnika s novodijagnosticiranom kroničnom mijeloičnom leukemijom (KML) s pozitivnim Philadelphia (Ph+) kromosomom (bcr-abl), u kojih se transplantacija koštane srži ne smatra prvom linijom liječenja. pedijatrijskih bolesnika s Ph+ KML-om u kroničnoj fazi nakon neuspjeha terapije interferonom- alfa, ili u ubrzanoj fazi ili u blastičnoj krizi. odraslih bolesnika s Ph+ KML-om u blastičnoj krizi. odraslih bolesnika s novodijagnosticiranom akutnom limfoblastičnom leukemijom s pozitivnim Philadelphia kromosomom (Ph+ ALL) uz kemoterapiju. odraslih bolesnika s recidivirajućim ili refraktornim Ph+ ALL-om u obliku monoterapije. odraslih bolesnika s mijelodisplastičnim/mijeloproliferativnim bolestima (MDS/MPD) povezanim s preraspodjelom gena za receptor za faktor rasta koji potječe od trombocita (PDGFR). odraslih bolesnika s uznapredovalim hipereozinofilnim sindromom (HES) i/ili kroničnom eozinofilnom leukemijom (KEL) s FIP1L1-PDGFRα preraspodjelom.
Imatinib Actavis is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Imatinib Actavis se ne smije upotrebljavati tijekom trudnoće, osim ako to nije neophodno, jer može naškoditi Vašem djetetu.
Imatinib Actavis is used in combination with other anticancer medicines in adults who have been newly diagnosed with Ph+ ALL.
Lijek Imatinib Actavis koristi se zajedno s drugim antikancerogenim lijekovima u odraslih bolesnika s novodijagnosticiranim Ph+ ALL-om.
Imatinib Actavis is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Lijek Imatinib Actavis koristi se za liječenje odraslih bolesnika s DFSP-om koji nisu podobni za kirurški zahvat i odraslih bolesnika koji nisu podobni za kirurški zahvat u slučaju kada je rak rekurentan nakon prethodnog liječenja ili je metastazirao u druge dijelove tijela.
Imatinib Actavis is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Lijek Imatinib Actavis koristi se za liječenje odraslih bolesnika s HES-om ili CEL-om sa specifičnom preraspodjelom dva gena naziva FIP1L1 i PDGFR; dermatofibrosarkomog protuberansa (DFSP), tipom raka (sarkoma) u kojem se stanice u tkivu ispod kože nekontrolirano dijele.
Imatinib Actavis is used when the patients are ‘Philadelphia-chromosome positive’ (Ph+).
Lijek Imatinib Actavis koristi se za liječenje bolesnika koji imaju „pozitivan Philadelphia kromosom” (Ph+).
Imatinib Actavis will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours.
Imatinib Actavis Vam može propisati jedino liječnik koji ima iskustva s lijekovima za liječenje raka krvi ili čvrstih tumora.
Imatinib and its metabolites are not excreted via the kidney to a significant extent.
Imatinib i njegovi metabolite ne izlučuju se u značajnoj mjeri putem bubrega.
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23 % (90 % CI [1.16 - 1.30]).
Imatinib 400 mg dvaput na dan imao je inhibitorni učinak na metabolizam metoprolola posredovan CYP2D6, pri čemu su se Cmax i AUC metoprolola povećali za otprilike 23 % (90 %CI [1,16–1,30]).
Imatinib did not interfere with the biotransformation of 5-fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (Ki - 34.7 µM).
Imatinib nije ometao biotransformaciju 5-fluorouracila, ali je inhibirao metabolizam paklitaksela, što je bila posljedica kompetitivne inhibicije CYP2C8 (Ki – 34,7 µM).
Imatinib in combination with chemotherapy induction (see Table 3) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients).
Imatinib u kombinaciji s indukcijskom kemoterapijom (vidjeti Tablicu 3) rezultirao je postizanjem stope potpunog hematološkog odgovora od 93% (147 od 158 procijenjenih bolesnika) i stope velikog citogenetskog odgovora od 90% (19 od 21 procijenjenog bolesnika).
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib.
Imatinib povećava srednju vrijednost Cmax i AUC simvastatina (CYP3A4 supstrat) za 2, odnosno 3,5 puta, što ukazuje na to da imatinib inhibira CYP3A4.
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib.
Imatinib povećava srednju vrijednost Cmax i AUC simvastatina (CYP3A4 supstrat) za 2-, odnosno 3,5 puta, što ukazuje na to da imatinib inhibira CYP3A4.
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).
Imatinib je mala molekula, inhibitor protein-tirozin kinaze, koja potentno inhibira aktivnost Bcr-Abl tirozin kinaze (TK), kao i nekoliko TK receptora: Kit, receptor za faktor matičnih stanica (SCF, engl. stem cell factor) kodiran c-Kit protoonkogenom, receptore za diskoidinsku domenu (DDR1 i DDR2, engl. discoidin domain receptors), receptor za faktor stimulacije kolonija (CSF-1R, engl. colony stimulating factor receptor) te alfa i beta receptore za faktor rasta koji potječe od trombocita (PDGFR- alfa i PDGFR-beta).
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Imatinib je također inhibitor receptorskih tirozin kinaza za faktor rasta koji potječe od trombocita (PDGF), PDGF-R,te inhibira stanična zbivanja posredovana PDGF-om .
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib je također inhibitor receptorskih tirozin kinaza za faktor rasta koji potječe od trombocita (PDGF), PDGF-R, i inhibira stanične događaje posredovane PDGF-om.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF),PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib je također inhibitor receptorskih tirozin kinaza za faktor rasta koji potječe od trombocita (PDGF), PDGF-R, te inhibira stanične događaje posredovane PDGF-om.
Imatinib may increase plasma concentration of other CYP3A4 metabolised medicinal products (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Imatinib može povećati koncentraciju drugih lijekova u plazmi koje metabolizira CYP3A4 (npr. triazolo-benzodiazepini, dihidropiridinski blokatori kalcijevih kanala, određeni inhibitori HMG-CoA reduktaze odnosno statini, itd.).
Imatinib medac 100 mg capsules are supplied in packs containing 60 capsules in blisters.
Imatinib medac 100 mg kapsule dostupne su u pakiranjima koja sadrže 60 kapsula u blisterima.
Imatinib medac 100 mg hard capsules
Imatinib medac 100 mg tvrde kapsule
Imatinib medac 100 mg hard capsules are gelatin capsules of size “3” with orange body and cap.
Imatinib medac 100 mg tvrde kapsule želatinske su kapsule veličine “3”, s narančastim tijelom i kapicom.
Imatinib medac 100 mg hard capsules Imatinib
Imatinib medac 100 mg tvrde kapsule imatinib
Imatinib medac 100 mg hard capsules Imatinib medac 400 mg hard capsules Imatinib
Imatinib medac 100 mg tvrde kapsule Imatinib medac 400 mg tvrde kapsule imatinib
Imatinib medac 400 mg hard capsules
Imatinib medac 400 mg tvrde kapsule
Imatinib medac 400 mg hard capsules are gelatin capsules of size “00” with caramel body and cap.
Imatinib medac 400 mg tvrde kapsule želatinske su kapsule veličine “00”, sa žuto-smećkastim tijelom i kapicom.
Imatinib medac 400 mg hard capsules Imatinib
Imatinib medac 400 mg tvrde kapsule imatinib
Imatinib medac is a ‘generic medicine’.
Lijek Imatinib medac je „generički lijek”.
Imatinib medac is also a treatment for children and adolescents for:
Također, Imatinib medac se koristi kod djece i adolescenata za liječenje:
Imatinib medac is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase. adult and paediatric patients with Ph+ CML in blast crisis. adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Imatinib medac indiciran je za liječenje pedijatrijskih bolesnika s novodijagnosticiranom kroničnom mijeloičnom leukemijom (KML) s pozitivnim Philadelphia (Ph+) kromosomom (bcr-abl), u kojih se transplantacija koštane srži ne smatra prvom linijom liječenja, pedijatrijskih bolesnika s Ph+ KML-om u kroničnoj fazi nakon neuspjeha terapije interferonom alfa, ili u ubrzanoj fazi, odraslih i pedijatrijskih bolesnika s Ph+ KML u blastičnoj krizi, odraslih i pedijatrijskih bolesnika s novodijagnosticiranom akutnom limfoblastičnom leukemijom s pozitivnim Philadelphia kromosomom (Ph+ ALL) uz kemoterapiju, odraslih bolesnika s recidivirajućim ili refraktornim Ph+ ALL-om u obliku monoterapije, odraslih bolesnika s mijelodisplastičnim/mijeloproliferativnim bolestima (MDS/MPD) povezanim s preraspodjelom gena za receptor za faktor rasta koji potječe od trombocita (PDGFR), odraslih bolesnika s uznapredovalim hipereozinofilnim sindromom (HES) i/ili kroničnom eozinofilnom leukemijom (KEL) s FIP1L1-PDGFR preraspodjelom, odraslih bolesnika s inoperabilnim dermatofibrosarkomom protuberans (DFSP) i odraslih bolesnika s rekurentnim i/ili metastazirajućim DFSP-om koji nisu podobni za kirurški zahvat.
Imatinib medac is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Imatinib medac se ne smije upotrebljavati tijekom trudnoće, osim ako to nije neophodno, jer može naškoditi Vašemu djetetu.
Imatinib medac is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Lijek Imatinib medac koristi se za liječenje bolesnika koji imaju „pozitivan Philadelphia kromosom” (Ph+).
Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters.
Imatinib Teva 100 mg filmom obložene tablete dostupne su u veličinama pakovanja od 20x1, 60x1, 120x1 ili 180x1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze.
Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 60 or 120 film-coated tablets in blisters.
Imatinib Teva 100 mg filmom obložene tablete dostupne su u veličinama pakovanja od 60 ili 120 filmom obloženih tableta u blisterima.
Imatinib Teva 100 mg film-coated tablets are dark yellow to brownish orange round film-coated tablets with a score line on one side.
Imatinib Teva 100 mg filmom obložene tablete su tamnožute do smećkasto narančaste okrugle filmom obložene tablete s razdjelnom crtom na jednoj strani.
Imatinib Teva 100 mg film-coated tablets imatinib
Imatinib Teva 100 mg filmom obložene tablete imatinib
Imatinib Teva 100 mg film-coated tablets Imatinib Teva 400 mg film-coated tablets
Imatinib Teva 100 mg filmom obložene tablete Imatinib Teva 400 mg filmom obložene tablete
Imatinib Teva 100 mg hard capsules are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters.
Imatinib Teva 100 mg tvrde kapsule dostupne su u veličinama pakiranja od 20x1, 60x1, 120x1 ili 180x1 tvrdih kapsula u perforiranim blisterima djeljivim na jedinične doze.
Imatinib Teva 100 mg hard capsules are available in pack sizes of 60 or 120 hard capsules in blisters.
Imatinib Teva 100 mg tvrde kapsule dostupne su u veličinama pakiranja od 60 ili 120 tvrdih kapsula u blisterima.
Imatinib Teva 100 mg hard capsules are non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap.
Imatinib Teva 100 mg tvrde kapsule su neprozirne narančaste kapsule s crnom oznakom 7629 na tijelu kapsule i crnom oznakom TEVA na kapici kapsule.
Imatinib Teva 100 mg hard capsules imatinib
Imatinib Teva 100 mg tvrde kapsule imatinib
Imatinib Teva 100 mg hard capsules Imatinib Teva 400 mg hard capsules
Imatinib Teva 100 mg tvrde kapsule Imatinib Teva 400 mg tvrde kapsule
Imatinib Teva 400 mg film-coated tablets are available in pack sizes of 30 or 90 film-coated tablets in blisters.
Imatinib Teva 400 mg filmom obložene tablete dostupne su u veličinama pakiranja od 30 ili 90 filmom obloženih tableta u blisterima.
Imatinib Teva 400 mg film-coated tablets are available in pack sizes of 30x1or 90x1 film-coated tablets in perforated unit dose blisters.
Imatinib Teva 400 mg filmom obložene tablete dostupne su u veličinama pakiranja od 30x1ili 90x1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze.
Imatinib Teva 400 mg film-coated tablets are dark yellow to brownish orange oblong film-coated tablets with a score line on one side.
Imatinib Teva 400 mg filmom obložene tablete su tamnožute do smećkasto narančaste duguljaste filmom obložene tablete s razdjelnom crtom na jednoj strani.
Imatinib Teva 400 mg film-coated tablets imatinib
Imatinib Teva 400 mg filmom obložene tablete imatinib
Imatinib Teva 400 mg hard capsules
Imatinib Teva 400 mg tvrde kapsule
Imatinib Teva 400 mg hard capsules are available in pack sizes of 30 or 90 hard capsules in blisters.
Imatinib Teva 400 mg tvrde kapsule dostupne su u veličinama pakiranja od 30 ili 90 tvrdih kapsula u blisterima
Imatinib Teva 400 mg hard capsules are available in pack sizes of 30x1 or 90x1 hard capsules in perforated unit dose blisters.
Imatinib Teva 400 mg tvrde kapsule dostupne su u veličinama pakiranja od 30x1 ili 180x1 tvrdih kapsula u perforiranim blisterima djeljivim na jedinične doze.
Imatinib Teva 400 mg hard capsules are non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
Imatinib Teva 400 mg tvrde kapsule su neprozirne narančaste kapsule s crnom oznakom 7630 na tijelu kapsule i crnom oznakom TEVA na kapici kapsule.
Imatinib Teva 400 mg hard capsules imatinib
Imatinib Teva 400 mg tvrde kapsule imatinib
Imatinib Teva can help you to fight this condition.
Imatinib Teva Vam može pomoći u borbi protiv te bolesti.
Imatinib Teva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Imatinib Teva izdaje se samo na liječnički recept te liječenje mora započeti i nadzirati liječnik koji je iskusan u liječenju raka krvi.
Imatinib Teva contains the active substance imatinib.
Imatinib Teva sadrži djelatnu tvar imatinib.
Imatinib Teva is a cancer medicine.
Imatinib Teva je lijek protiv raka.
Imatinib Teva is a medicine containing an active substance called imatinib.
Imatinib Teva je lijek koji sadrži djelatnu tvar zvanu imatinib.
Imatinib Teva is a treatment for adults and children for:
Imatinib Teva se kod odraslih osoba i djece koristi za liječenje :
Imatinib Teva is a treatment for adults and children for:
Imatinib Teva se kod odraslih osoba i djece koristi za liječenje:
Imatinib Teva is also a treatment for adults for:
Imatinib Teva se kod odraslih osoba također koristi za liječenje:
Imatinib Teva is also a treatment for children and adolescents with CML.
Imatinib Teva se kod djece i adolescenata također koristi za liječenje KML-a.
Imatinib Teva is indicated for
Imatinib Teva je indiciran za
Imatinib Teva is indicated for the treatment of
Imatinib Teva je indiciran za liječenje
Imatinib Teva is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Imatinib Teva se ne smije upotrebljavati tijekom trudnoće, osim ako to nije neophodno.
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after
Liječenje imatinibom izazvalo je brzi odgovor pedijatrijskih bolesnika s novodijagnosticiranim KML-om sa CHR-om od
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy.
Liječenje imatinibom izazvalo je brzi odgovor u novodijagnosticiranih pedijatrijskih KML bolesnika sa PHO- om od 78% nakon 8 tjedana terapije.
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy.
Liječenje imatinibomizazvalo je brzi odgovor u novodijagnosticiranih pedijatrijskih KML bolesnika sa PHO-om od 78% nakon 8 tjedana terapije.
Imatinib was not considered genotoxic when tested in an in vitro bacterial cell assay (Ames test), an in vitro mammalian cell assay (mouse lymphoma) and an in vivo rat micronucleus test.
Imatinib nije smatran genotoksičnim kada je ispitivan u in vitro pokusu na uzorku bakterijskih stanica (Ames test), u in vitro pokusu na uzorku stanica sisavaca (mišji limfom) te u in vivo testu na mikronukleusu štakora.
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Imatinib je bio teratogen u štakora kada je primjenjivan tijekom organogeneze u dozama ≥100 mg/kg, koje su približno jednake maksimalnoj kliničkoj dozi od 800 mg/dan, temeljeno na veličini površine tijela.
imatinib – anticancer (used to treat cancer)
imatinib – lijek protiv raka (primjenjuje se za liječenje raka)
imatinib, lapatinib (used to treat cancer)
imatinib, lapatinib (koriste se za liječenje raka)
imatinib, used to inhibit the growth of abnormal cells. angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
imatinib, lijek koji se koristi za usporavanje rasta abnormalnih stanica. inhibitori angiotenzin konvertirajućeg enzima (ACE) (poput ramiprila) koji se koriste za liječenje visokog krvnog tlaka ili drugih kardiovaskularnih problema.
imatinib, used to inhibit the growth of abnormal cells. angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
imatinib, lijek koji zaustavlja rast abnormalnih stanica. inhibitori angiotenzin konvertirajućeg enzima (ACE) (poput ramiprila) koji se koriste za liječenje visokog krvnog tlaka ili drugih kardiovaskularnih problema.
imatinib, used to treat a type of leukaemia. crizotinib, used to treat a type of lung cancer called non-small cell lung cancer.
imatinib, koristi se za liječenje jedne vrste leukemije; krizotinib, koristi se za liječenje jedne vrste raka pluća koja se zove rak pluća nemalih stanica
Imatinib-intolerant patients
bolesnici koji ne podnose imatinib
Imatinib-resistant or intolerant CML in accelerated phase at 400 mg twice daily
Ubrzana faza KML-a s rezistencijom ili intolerancijom na imatinib uz primjenu 400 mg dva puta na dan
Imatinib-resistant or intolerant CML-CP and CML-AP
KML u kroničnoj i ubrzanoj fazi s rezistencijom ili intolerancijom na imatinib
Imatinib-resistant patients
bolesnici otporni na imatinib
Imatinib-resistant patients 44% (35–53) Major molecular response in patients achieving CCyRd (%) (95% CI)
bolesnici otporni na imatinib 44% (35–53) Značajan molekularni odgovor u bolesnika koji su postigli CCyRd (%) (95% CI)
Imatinib-resistant patients 72% (58–83)
Bolesnici otporni na imatinib 72% (58–83)
IMBRUVICA 140 mg capsules ibrutinib
IMBRUVICA 140 mg kapsule ibrutinib
IMBRUVICA 140 mg hard capsules.
IMBRUVICA 140 mg tvrde kapsule.
IMBRUVICA are white opaque, hard capsules marked with “ibr 140 mg” in black ink on one side.
IMBRUVICA su bijele neprozirne tvrde kapsule označene s “ibr 140 mg” crnom bojom na jednoj strani.
IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).
IMBRUVICA je u monoterapiji indicirana za liječenje odraslih bolesnika s prethodno neliječenom kroničnom limfocitnom leukemijom (KLL) (vidjeti dio 5.1).